Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
ListedSMEMAHALIFE

Mahamaya Lifesciences IPO

Mahamaya Lifesciences IPO is an SME IPO raising ₹70 Cr at ₹108 – ₹114 a share. It listed on 18 Nov 2025 at ₹116, +1.8% against its issue price of ₹114, and trades at ₹178 today (+55.9% since issue). It was subscribed 1.69× in total.

Get alerts on this companyCompany pageProspectus ↗
₹114
Issue price
₹178
Price now
+55.9%
Since issue price
18 Nov 2025
Listed on
1.69×Subscribed (final) · all exchanges

Just covered — bids slightly exceed the shares on offer

populated partly populated we hold nothing here — the tab says why

How its cohort has done

268 SME issues listed in 2025 that we can price today. This is the group this issue belongs to.

−7.6%
Median return since issue price
54.1%
Now trading below their issue price

Neither figure is a forecast for this issue — they describe what happened to comparable issues. Full cohort analytics →

What we hold for this issue

Stated up front on every issue, so a sparse page reads as a fact about the source rather than a broken one.

Category split — who bidNot available from NSE for this issue
How demand built over timeFinal figure held, but no series — we were not sampling this issue while it was live
Price-point demand curveLive only — NSE stops serving this once bidding closes
Lead managers and registrarNot published — smaller SME issues often name none
Official documents1 document
Listing-day priceOpened at ₹116 on debut
Performance since listingComputed from our own daily closes

What happens when

10 NovPre-apply
11 NovBidding opens
13 NovBidding closes
17 NovAllotment
17 NovRefunds
18 NovListing
25 DecMandate ends

Track MAHAMAYA LIFESCIENCES LIMITED

Results, orders, board decisions and every other filing — summarised and sent to your WhatsApp the minute they are out.

Open the company page

Figures are as published by the exchanges and the issuer’s prospectus. MarketPing publishes facts, comparisons and history only — nothing here is a recommendation to apply to this issue, and we do not publish grey market premium.